title: Accumulation of cis-diamminedichloroplatinum (II) and its analogues in sensitive and resistant human ovarian carcinoma cells.
abstract: Human ovarian carcinoma cell line (NOS2), established from a patient with serous cystadenocarcinoma of the ovary, has been exposed to a stepwise increase in cis-diamminedichloroplatinum (II) (CDDP) concentration to produce a CDDP-resistant cell line NOS2CR) as an experimental model for resistance to CDDP. NOS2CR cells showed a 7-fold resistance to CDDP and a lesser degree of cross-resistance to diammine (1,1-cyclobutanedicarboxylato)-platinum (II) (CBDCA) and (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato) platinum (II) (DWA2114R). In the absence of CDDP, cross-resistance to DWA2114R was reduced to the original level by 2 months, although 83% resistance to CDDP remained up to 6 months. To investigate CDDP-resistant mechanisms, alterations in the intracellular accumulation of CDDP and analogues were assayed by atomic absorption. In both NOS2 and NOS2CR cells, accumulation of CDDP increased linearly with time and was concentration-dependent. NOS2CR cells demonstrated 71, 52 and 12% reduction in accumulation of CDDP, CBDCA, and DWA2114R, respectively. These reductions did not seem to be due to P-glycoprotein, because expression of multidrug-resistant 1 gene was not detected in either NOS2 or NOS2CR cells. These studies indicate that the mechanisms of resistance to CDDP and analogues in NOS2CR cells are related in the main to reduced intracellular accumulation of drugs. DWA2114R might be helpful to treat CDDP-resistant and recurrent tumors which were treated by CDDP.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Misawa
authors.forename: F
authors.initials: F
authors.lastname: Kikkawa
authors.forename: H
authors.initials: H
authors.lastname: Oguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Morikawa
authors.forename: M
authors.initials: M
authors.lastname: Kawai
authors.forename: O
authors.initials: O
authors.lastname: Maeda
authors.forename: M
authors.initials: M
authors.lastname: Iwata
authors.forename: T
authors.initials: T
authors.lastname: Kano
authors.forename: Y
authors.initials: Y
authors.lastname: Furuhashi
authors.forename: Y
authors.initials: Y
authors.lastname: Tomada
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D016190:Carboplatin / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D002945:Cisplatin / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D003536:Cystadenocarcinoma / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C058816:DWA 2114; D016190:Carboplatin; D002945:Cisplatin